메뉴 건너뛰기




Volumn 87, Issue 4, 2013, Pages 267-273

Parkinson disease: An update

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; APOMORPHINE; BENZATROPINE; BOTULINUM TOXIN A; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DESIPRAMINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLYCOPYRRONIUM BROMIDE; LISURIDE; MACROGOL; MACROGOL 3350; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; OLANZAPINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SILDENAFIL; TOLCAPONE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

EID: 84874913947     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (130)

References (35)
  • 1
    • 66949117423 scopus 로고    scopus 로고
    • The scientific and clinical basis for the treatment of Parkinson disease (2009)
    • Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 suppl 4): S1-S136.
    • (2009) Neurology , vol.72 , Issue.21 SUPPL. 4
    • Olanow, C.W.1    Stern, M.B.2    Sethi, K.3
  • 3
    • 33745919520 scopus 로고    scopus 로고
    • Epidemiology of Parkinson's disease
    • de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-535.
    • (2006) Lancet Neurol , vol.5 , Issue.6 , pp. 525-535
    • de Lau, L.M.1    Breteler, M.M.2
  • 4
    • 78649293807 scopus 로고    scopus 로고
    • Scottish Intercollegiate Guidelines Network, Edinburgh: Scottish Intercollegiate Guidelines Network; January, Accessed March 8, 2011
    • Scottish Intercollegiate Guidelines Network. Diagnosis and Pharmacological Management of Parkinson's disease: A National Clinical Guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; January 2010. http://www.sign.ac.uk/pdf/sign113.pdf. Accessed March 8, 2011.
    • (2010) Diagnosis and Pharmacological Management of Parkinson's Disease: A National Clinical Guideline
  • 5
    • 73949149476 scopus 로고    scopus 로고
    • Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland
    • Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord. 2009;24(16):2379-2385.
    • (2009) Mov Disord , vol.24 , Issue.16 , pp. 2379-2385
    • Newman, E.J.1    Breen, K.2    Patterson, J.3    Hadley, D.M.4    Grosset, K.A.5    Grosset, D.G.6
  • 6
    • 0036829811 scopus 로고    scopus 로고
    • How valid is the clinical diagnosis of Parkinson's disease in the community?
    • Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry. 2002;73(5):529-534.
    • (2002) J Neurol Neurosurg Psychiatry , vol.73 , Issue.5 , pp. 529-534
    • Schrag, A.1    Ben-Shlomo, Y.2    Quinn, N.3
  • 7
    • 79955950682 scopus 로고    scopus 로고
    • Differentiation and diagnosis of tremor
    • Crawford P, Zimmerman EE. Differentiation and diagnosis of tremor. Am Fam Physician. 2011;83(6):697-702.
    • (2011) Am Fam Physician , vol.83 , Issue.6 , pp. 697-702
    • Crawford, P.1    Zimmerman, E.E.2
  • 8
    • 29044435205 scopus 로고    scopus 로고
    • The diagnosis of Parkinson's disease
    • Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 2006;5(1):75-86.
    • (2006) Lancet Neurol , vol.5 , Issue.1 , pp. 75-86
    • Tolosa, E.1    Wenning, G.2    Poewe, W.3
  • 9
    • 33646082990 scopus 로고    scopus 로고
    • Practice parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968-975.
    • (2006) Neurology , vol.66 , Issue.7 , pp. 968-975
    • Suchowersky, O.1    Reich, S.2    Perlmutter, J.3    Zesiewicz, T.4    Gronseth, G.5    Weiner, W.J.6
  • 10
    • 0037438933 scopus 로고    scopus 로고
    • Does this patient have Parkinson disease?
    • Rao G, Fisch L, Srinivasan S, et al. Does this patient have Parkinson disease? JAMA. 2003;289(3):347-353.
    • (2003) JAMA , vol.289 , Issue.3 , pp. 347-353
    • Rao, G.1    Fisch, L.2    Srinivasan, S.3
  • 11
    • 33745988951 scopus 로고    scopus 로고
    • The National Collaborating Centre for Chronic Conditions, London: Royal College of Physicians, Accessed March 8, 2011
    • The National Collaborating Centre for Chronic Conditions. Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians; 2006. http://www.nice.org.uk/nicemedia/live/10984/30087/30087.pdf. Accessed March 8, 2011.
    • (2006) Parkinson's Disease: National Clinical Guideline For Diagnosis and Management In Primary and Secondary Care
  • 13
    • 42049114224 scopus 로고    scopus 로고
    • Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study
    • Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology. 2008;70(16 pt 2):1423-1430.
    • (2008) Neurology , vol.70 , Issue.16 Pt 2 , pp. 1423-1430
    • Driver, J.A.1    Kurth, T.2    Buring, J.E.3    Gaziano, J.M.4    Logroscino, G.5
  • 14
    • 23844437947 scopus 로고    scopus 로고
    • Prognosis of Parkinson disease: Risk of dementia and mortality: The Rotterdam Study
    • de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005; 62(8):1265-1269.
    • (2005) Arch Neurol , vol.62 , Issue.8 , pp. 1265-1269
    • de Lau, L.M.1    Schipper, C.M.2    Hofman, A.3    Koudstaal, P.J.4    Breteler, M.M.5
  • 15
    • 0037039267 scopus 로고    scopus 로고
    • Practice parameter: Initiation of treatment for Parkinson's disease: An evidencebased review: Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidencebased review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002; 58 (1): 11-17.
    • (2002) Neurology , vol.58 , Issue.1 , pp. 11-17
    • Miyasaki, J.M.1    Martin, W.2    Suchowersky, O.3    Weiner, W.J.4    Lang, A.E.5
  • 17
    • 77950179361 scopus 로고    scopus 로고
    • Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
    • Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev. 2009;(4):CD006661.
    • (2009) Cochrane Database Syst Rev , Issue.4
    • Caslake, R.1    Macleod, A.2    Ives, N.3    Stowe, R.4    Counsell, C.5
  • 19
    • 0035845719 scopus 로고    scopus 로고
    • The use of alternative therapies by patients with Parkinson's disease
    • Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson's disease. Neurology. 2001;57(5):790-794.
    • (2001) Neurology , vol.57 , Issue.5 , pp. 790-794
    • Rajendran, P.R.1    Thompson, R.E.2    Reich, S.G.3
  • 20
    • 33646104205 scopus 로고    scopus 로고
    • Practice parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • published correction appears in Neurology. 2006;67(2):299
    • Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2006;67(2):299]. Neurology. 2006;66(7):976-982.
    • (2006) Neurology , vol.66 , Issue.7 , pp. 976-982
    • Suchowersky, O.1    Gronseth, G.2    Perlmutter, J.3    Reich, S.4    Zesiewicz, T.5    Weiner, W.J.6
  • 21
    • 33646076457 scopus 로고    scopus 로고
    • Practice parameter: Treatment of Parkinson disease with motor fuctuations and dyskinesia (an evidencebased review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fuctuations and dyskinesia (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995.
    • (2006) Neurology , vol.66 , Issue.7 , pp. 983-995
    • Pahwa, R.1    Factor, S.A.2    Lyons, K.E.3
  • 22
    • 84921705486 scopus 로고    scopus 로고
    • Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease
    • Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2004;(4):CD004554.
    • (2004) Cochrane Database Syst Rev , Issue.4
    • Deane, K.H.1    Spieker, S.2    Clarke, C.E.3
  • 23
    • 77955501449 scopus 로고    scopus 로고
    • Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications
    • Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7): CD007166.
    • (2010) Cochrane Database Syst Rev , Issue.7
    • Stowe, R.1    Ives, N.2    Clarke, C.E.3
  • 24
    • 79951526730 scopus 로고    scopus 로고
    • Deep brain stimulation for Parkinson disease: An expert consensus and review of key issues
    • Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011; 68 (2): 165-171.
    • (2011) Arch Neurol , vol.68 , Issue.2 , pp. 165-171
    • Bronstein, J.M.1    Tagliati, M.2    Alterman, R.L.3
  • 25
    • 58149385649 scopus 로고    scopus 로고
    • CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: A randomized controlled trial
    • Weaver FM, Follett K, Stern M, et al.; CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.
    • (2009) JAMA , vol.301 , Issue.1 , pp. 63-73
    • Weaver, F.M.1    Follett, K.2    Stern, M.3
  • 26
    • 33748139412 scopus 로고    scopus 로고
    • German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease
    • [published correction appears in N Engl J Med. 20 06;355 (12):1289]
    • Deuschl G, Schade-Brittinger C, Krack P, et al.; German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease [published correction appears in N Engl J Med. 20 06;355 (12):1289]. N Engl J Med. 2006;355(9):896-908.
    • (2006) N Engl J Med , vol.355 , Issue.9 , pp. 896-908
    • Deuschl, G.1    Schade-Brittinger, C.2    Krack, P.3
  • 27
    • 53749108385 scopus 로고    scopus 로고
    • Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease
    • Schiftto G, Friedman JH, Oakes D, et al.; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008;71(7):481-485.
    • (2008) Neurology , vol.71 , Issue.7 , pp. 481-485
    • Schiftto, G.1    Friedman, J.H.2    Oakes, D.3
  • 28
    • 77950475028 scopus 로고    scopus 로고
    • Practice parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924-931.
    • (2010) Neurology , vol.74 , Issue.11 , pp. 924-931
    • Zesiewicz, T.A.1    Sullivan, K.L.2    Arnulf, I.3
  • 29
    • 33748677085 scopus 로고    scopus 로고
    • Excessive daytime sleepiness in Parkinson disease: Is it the drugs or the disease?
    • Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen J.P. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology. 2006;67(5):853-858.
    • (2006) Neurology , vol.67 , Issue.5 , pp. 853-858
    • Gjerstad, M.D.1    Alves, G.2    Wentzel-Larsen, T.3    Aarsland, D.4    Larsen, J.P.5
  • 30
    • 80155208344 scopus 로고    scopus 로고
    • Associated factors for REM sleep behavior disorder in Parkinson disease
    • Sixel-Döring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology. 2011;77 (11):1048-1054.
    • (2011) Neurology , vol.77 , Issue.11 , pp. 1048-1054
    • Sixel-Döring, F.1    Trautmann, E.2    Mollenhauer, B.3    Trenkwalder, C.4
  • 31
    • 27144469563 scopus 로고    scopus 로고
    • Rapid eye movement sleep parasomnias
    • Schenck CH, Mahowald MW. Rapid eye movement sleep parasomnias. Neurol Clin. 2005; 23 (4): 1107-1126.
    • (2005) Neurol Clin , vol.23 , Issue.4 , pp. 1107-1126
    • Schenck, C.H.1    Mahowald, M.W.2
  • 32
    • 77950927299 scopus 로고    scopus 로고
    • Glycopyrrolate for sialorrhea in Parkinson disease: A randomized, double-blind, crossover trial
    • Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. 2010;74(15):1203-1207.
    • (2010) Neurology , vol.74 , Issue.15 , pp. 1203-1207
    • Arbouw, M.E.1    Movig, K.L.2    Koopmann, M.3
  • 33
    • 14944354884 scopus 로고    scopus 로고
    • Sydney Multicenter Study of Parkinson's Disease: Non-L-dopa-responsive problems dominate at 15 years
    • Hely MA, Morris JG, Reid WG, Traffcante R. Sydney Multicenter Study of Parkinson's Disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190-199.
    • (2005) Mov Disord , vol.20 , Issue.2 , pp. 190-199
    • Hely, M.A.1    Morris, J.G.2    Reid, W.G.3    Traffcante, R.4
  • 34
    • 33646107153 scopus 로고    scopus 로고
    • Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996-1002.
    • (2006) Neurology , vol.66 , Issue.7 , pp. 996-1002
    • Miyasaki, J.M.1    Shannon, K.2    Voon, V.3
  • 35
    • 64049105010 scopus 로고    scopus 로고
    • A controlled trial of antidepressants in patients with Parkinson disease and depression
    • Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886-892.
    • (2009) Neurology , vol.72 , Issue.10 , pp. 886-892
    • Menza, M.1    Dobkin, R.D.2    Marin, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.